Speeding access to innovative hepatitis C products: Unitaid’s key role
Where are we today?
Karin Timmermans
Unitaid
Unitaid’s HCV Portfolio – an overview
The market for DAAs – a snapshot
Major challenges in HCV

Unitaid started to explore the HCV market in 2013. The supply and demand cycle was blocked at virtually all points.

Supply
- Lack of suitable tests
- Lack of affordable treatment

Demand
- Lack of data on the epidemic
  - Who to treat?
- Lack of guidelines for implementation
  - How to treat?
- Lack of national programmes, policies & budget
Major challenges in HCV

This was further aggravated by a lack of awareness.
Unitaid’s HCV portfolio

Through its projects, Unitaid is addressing several challenges simultaneously. This has contributed to a supply and demand cycle that is starting to function – and, importantly, it has contributed to increasing access.

Subsequent presentations provide examples of some of the projects’ achievements. (NB: due to time constraints, these are *not* comprehensive overviews of the projects’ achievements – it is only giving a flavour).

<table>
<thead>
<tr>
<th>Issue</th>
<th>Project</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lack of suitable tests</td>
<td>FIND</td>
</tr>
<tr>
<td>High medicines prices</td>
<td>MPP, MSF</td>
</tr>
<tr>
<td>Complex algorithms/care model</td>
<td>MSF</td>
</tr>
<tr>
<td>Lack of demand/awareness</td>
<td>Coalition Plus</td>
</tr>
<tr>
<td>Product quality unclear</td>
<td>WHO prequalification</td>
</tr>
<tr>
<td>Lack of guidelines</td>
<td>WHO Hepatitis programme</td>
</tr>
</tbody>
</table>
Unitaid’s HCV Portfolio – an overview

The market for DAAs – a snapshot
Estimating access

Unitaid has estimated the number of people that have access to originator and generic DAAs (see next slides), using access to sofosbuvir-based treatments as an indicator.

The estimates related to generic sofosbuvir-based treatments are conservative (low-end) estimates; they do not include treatments made from raw materials produced outside India (due to non-availability of data).
Estimated number of people treated with SOF-based regimens - originator

Source of data: Gilead
Conservative estimate of the number of people treated with SOF-based regimens (originator and generic)

For methods and limitations, see Unitaid Technology and Market Landscape Hepatitis C Medicines, August 2017
Key trends

Access to sofosbuvir-based HCV treatments has increased consistently since 2014; however the increase appears to be slowing down*.

The number of people accessing generic treatments is larger than the number of people accessing the originator products.

* This may be compensated by increased use of medicines whose raw materials are not produced in India.
Presentations by grantees

Médecins Sans Frontières (MSF)
Coalition Plus
Medicines Patent Pool (MPP)
FIND
WHO